<DOC>
	<DOCNO>NCT00526877</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety long-acting risperidone microspheres ( small uniformly-sized spherical particle , micrometer dimension , frequently label radioisotope various reagent act tags marker ) participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) schizoaffective disorder ( mixed psychiatric disorder relate complex psychotic state feature schizophrenia mood disorder bipolar disorder ) , receive psychiatric home-care treatment .</brief_summary>
	<brief_title>An Efficacy Safety Study Long-acting Risperidone Participants With Schizophrenia Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-centric ( conducted one center ) , non-randomized single-arm study long- act risperidone microspheres participant schizophrenia schizoaffective disorder . The duration study 6 month include follow part : Screening ( , 28 day study commences Day 1 ) , run-in period ( , Week 1 3 ) Treatment period ( , Week 1 24 ) . Participants receive previous medication first three week run-in period previous medication taper third week . Participants receive long-acting risperidone microspheres start dose 25 milligram ( mg ) every two week intramuscular injection ( injection substance muscle ) . Efficacy participant primarily evaluate Positive Negative Syndrome Scale .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Meet diagnostic criterion schizophrenia schizoaffective disorder accord Diagnostic Statistical Manual Mental Disorders , fourth edition ( DSMIV ) Participant give adequate dose appropriate antipsychotic adequate period time prior enrollment , previous treatment consider unsatisfactory due one follow reason : lack efficacy , lack tolerability safety , lack compliance and/or reason switch another antipsychotic medication Female participant must postmenopausal , surgically sterile , practice effective method birth control entry throughout study ; negative urine betahuman chorionic gonadotropin ( HCG ) pregnancy test screening ; negative urine pregnancy test screen visit Participants legally acceptable representative must sign informed consent document Participants primary , active DSMIV diagnosis schizophrenia schizoaffective disorder Participants relevant history current presence significant and/or unstable cardiovascular , respiratory , neurological ( include seizure significant cerebrovascular ) , renal , hepatic , hematologic , endocrine , immunologic systemic disease Participants previously concomitant use Risperdal CONSTA History current symptom tardive dyskinesia History neuroleptic malignant syndrome ( NMS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective disorder</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Risperdal Consta</keyword>
</DOC>